Biocept Inc. (NASDAQ: BIOC) announced that its blood-based diagnostic,
OncoCEE-BR, was used to determine hormonal status of metastatic breast
cancer patients in a prospective study at Columbia University in New York.
Read more: Biocept Breaks Through With Columbia Study (NASDAQ: BIOC) - 24/7
Wall St. http://247wallst.com/healthcare-business/2015/02/23/biocept-breaks-through-with-columbia-study/#ixzz3SgxkmKB2
Follow us: @247wallst on Twitter | 247wallst on Facebook